One To Watch

Arcturus Therapeutics

A messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics using proprietary LUNAR lipid delivery and STARR self-amplifying mRNA technologies.

Company Overview

A messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics using proprietary LUNAR lipid delivery and STARR self-amplifying mRNA technologies. Arcturus combines three enabling platforms to develop treatments for rare genetic diseases and infectious diseases. The company operates primarily in rare disease therapeutics while maintaining a vaccine platform capability.

Headquarters and Global Presence

Arcturus is headquartered in San Diego, California, operating as a US-based biotechnology company. The company maintains a focused regional presence with operations centered in its California facility.

Founding and History

Founded in 2013, Arcturus Therapeutics went public on NASDAQ under the ticker ARCT. The company was established to develop RNA-based medicines using novel delivery and mRNA amplification technologies. Arcturus has evolved from early-stage platform development to clinical-stage programs in rare diseases.

Therapy Areas and Focus

The company targets liver and respiratory rare diseases where genetic deficiencies create significant unmet medical need. Arcturus focuses on conditions amenable to mRNA replacement therapy, particularly hereditary diseases affecting protein production. The rare disease focus allows for orphan drug designation pathways and specialized regulatory interactions.

Technology Platforms and Modalities

Arcturus operates three core platforms: LUNAR lipid-mediated delivery for tissue-specific targeting, STARR self-amplifying mRNA (sa-mRNA) for enhanced protein expression, and conventional mRNA drug capabilities. The self-amplifying approach potentially requires lower doses than traditional mRNA by replicating within cells. LUNAR enables organ-specific delivery, particularly to liver tissue where many rare disease targets reside.

Key Pipeline and Programs

The lead program ARCT-810 targets ornithine transcarbamylase (OTC) deficiency, a rare liver disorder, currently in clinical development. The company's vaccine platform demonstrated efficacy in a Phase III COVID-19 study using sa-mRNA technology, branded as KOSTAIVE. Additional rare disease programs target respiratory conditions and other genetic deficiencies using the same platform technologies. The pipeline spans preclinical through late-stage clinical development.

Key Personnel

Joseph E. Payne serves as President and CEO, leading the company's strategic direction and clinical development programs. Peter Farrell acts as Chairman of the Board. Padmanabh Chivukula holds the position of Chief Scientific Officer and Chief Operating Officer, overseeing platform development and operations.

Strategic Partnerships

Arcturus established a significant global collaboration and licensing agreement with CSL for vaccine platform technology, providing access to the sa-mRNA platform. The CSL partnership validates the STARR technology following successful Phase III vaccine results. The company maintains a mixed strategy of internal development for rare diseases while partnering for vaccine applications.

FAQ Section

Successfully transitioning from platform validation through COVID-19 vaccines to proving clinical efficacy in rare disease therapeutics. The company must demonstrate that its sa-mRNA and LUNAR delivery technologies can achieve therapeutic benefit in genetic diseases.

Self-amplifying mRNA replicates within cells to produce more sustained protein expression than conventional mRNA, potentially enabling lower dosing and longer duration of effect. This could improve the therapeutic window and reduce manufacturing costs for chronic rare disease treatments.

The combination of STARR self-amplifying mRNA with LUNAR tissue-specific lipid delivery creates a dual advantage over standard mRNA therapies. While competitors use conventional mRNA, Arcturus' sa-mRNA platform potentially offers enhanced potency and duration with targeted organ delivery.

ARCT-810 for OTC deficiency represents the lead validation of Arcturus' rare disease strategy, targeting a life-threatening genetic disorder with limited treatment options. Success could establish proof-of-concept for the sa-mRNA platform in metabolic rare diseases.

Liver and respiratory rare diseases dominate the pipeline, focusing on genetic deficiencies where mRNA replacement therapy can restore missing or deficient proteins. The company also maintains infectious disease vaccine capabilities through platform partnerships.

Arcturus operates as a clinical-stage biotechnology company with programs ranging from preclinical rare disease candidates to late-stage vaccine platform validation. The company has transitioned from pure platform development to clinical execution across multiple indications.

Key catalysts and risks to monitor include:

• Clinical data readouts from ARCT-810 OTC deficiency program

• Progression of additional rare disease candidates into clinical trials

• Manufacturing scale-up capabilities for sa-mRNA production

• Regulatory pathway navigation for rare disease indications

Want to Update your Company's Profile?